Clinical Trial

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

Name: Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer — clinical trial record (NCT07500298)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

To learn if SAR445877 in combination with FOLFOX6 and bevacizumab can be safely given to patients with advanced MSS CRC.

Protocol Amendment History 1 change

critical Recruitment opened 2026-06-02

Trial Details

NCT Number	NCT07500298
Lead Sponsor	M.D. Anderson Cancer Center Collaborators: Sanofi
Conditions	Phase 1, SAR445877, FOlfox6, Bevacizimab, First Line Treatment, Metastatic Colorectal Cancer (CRC), Microsatellite Stable
Enrollment	41 participants
Start Date	2026-05-20
Primary Completion	2030-12-27 (estimated)
Study Completion	2032-12-27 (estimated)
Updated on ClinicalTrials.gov	2026-07-23